NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer
(WorldNews Health)

- 20 Years` Industry Experience Managing Biotech Companies in US and Europe - Aim to Maximize Potential of ADC Platform and Accelerate Clinical Development of Lead Compound an Anti-ROR1 Antibody Drug Conjugate BASEL, Switzerland, Aug. 3, 2020 /PRNewswire/ -- NBE-Therapeutics, the Swiss-based company developing best in class cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform, announces the appointment of Bertrand Damour as Chief Executive Officer. Bertrand Damour has 20 years` management experience in the biotech industry in Europe and US as CEO of biotech companies and in the banking...